Skip to main content
SpringerLink
Log in

Role of impaired insulin secretion and insulin resistance in the pathogenesis of type 2 diabetes mellitus

  • Original Article
  • Published:
Comprehensive Therapy

Abstract

Type 2 diabetes mellitus (T2DM) is a heterogenous disorder caused by a combination of genetic and acquired abnormalities that affect insulin sensitivity and insulin secretion. Currently available data suggest that insulin resistance is the acquired defect largely secondary to unhealthy lifestyles and that the major genetic factor is impaired insulin secretion. The latter is the result of both reduced β-cell mass and functional abnormalities makes the β-cell unable to compensate for increased insulin requirements caused by insulin resistance. Targeting both insulin resistance and impaired insulin secretion is therefore appropriate to prevent T2DM and to improve glycemic control in those with the disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. National diabetes fact sheet: General information and national estimates on diabetes in the United States. Centers for Disease Control and Prevention 2003. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Washington, DC.

  2. Harris M, Flegal K, Cowie C, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 1998;21:518–524.

    Article  CAS  PubMed  Google Scholar 

  3. Himsworth H, Kerr R. Insulin-sensitive and insulin-insensitive types of diabetes mellitus. Clin Sci 1939;4:119–152.

    CAS  Google Scholar 

  4. Byrne M, Sturgis J, Sobel R, Polonsky K. Elevated plasma glucose 2h postchallenge predicts defects in B-cell function. Am J Physiol 1996;270:E572-E579.

    CAS  PubMed  Google Scholar 

  5. Eriksson J, Franssila-Kallunki A, Ekstand A, et al. Early metabolic defects in persons at increased risk for noninsulin-dependent diabetes mellitus. N. Engl J Med 1989;321:337–343.

    Article  CAS  PubMed  Google Scholar 

  6. Weyer C, Tataranni PA, Bogardus C, Pratley R. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 2000;24:89–94.

    Article  Google Scholar 

  7. Matthews D, Cull C, Stratton I, Holman R, Turner R. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabet Med 1998;15:297–303.

    Article  CAS  PubMed  Google Scholar 

  8. DeFronzo R. The triumvirate: B-cell, muscle, and liver: a collusion responsible for NIDDM. Diabetes 1988;37:667–687.

    Article  CAS  PubMed  Google Scholar 

  9. DeFronzo R, Bonadonna R, Ferrannini E. Pathogenesis of NIDDM. In: International Textbook of Diabetes Mellitus. (Alberti K, Zimmet P, DeFronzo R, eds) Wiley, New York, 1997, 635–712.

    Google Scholar 

  10. Olefsky J. Diabetes Mellitus (Type II): Etiology and pathogenesis. In: Ehdocrinology. (DeGroot L, Besser M, Burger H, et al. eds.) W. B. Saunders, Philadelphia, 1995, 1436–1463.

    Google Scholar 

  11. Gerich J. Is insulin resistance the principal cause of type 2 diabetes? Diabetes, Obesity and Metabolism 1999;1:257–263.

    Article  CAS  Google Scholar 

  12. Van Haeften T, Pimenta W, Mitrakou A, et al. Relative contributions of b-cell function and tissue insulin sensitivity to fasting and postglucose-load glycemia. Metabolism 2000;49:1318–1325.

    Article  PubMed  Google Scholar 

  13. Lillioja S, Mott D, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima Indians. N Engl J Med 1993;329:1988–1992.

    Article  CAS  PubMed  Google Scholar 

  14. Lillioja S, Mott D, Howard B, et al. Impaired glucose tolerance as a disorder of insulin action: longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 1988;318:1217–1225.

    Article  CAS  PubMed  Google Scholar 

  15. Martin B, Warram J, Krolewski A, Bergman R, Soeldner J, Kahn C. Role of glucose and insulin resistance in development of type II diabetes mellitus: results of a 25-year follow-up study. Lancet 1992; 340:925–929.

    Article  CAS  PubMed  Google Scholar 

  16. Gulli G, Ferrannini E, Stern M, Haffner S, DeFronzo R. The metabolic profile of NIDDM is fully established in glucose-tolerant off-spring of two Mexican-American NIDDM parents. Diabetes 1992;41:1575–1586.

    Article  CAS  PubMed  Google Scholar 

  17. Warram J, Martin B, Krolewski A, Soeldener S, Kahn C. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Int Med 1990;113:909–915.

    Article  CAS  PubMed  Google Scholar 

  18. Boden G, Chen X, Polansky M. Disruption of circadian insulin secretion is associated with reduced glucose uptake in first-degree relatives of patients with type 2 diabetes. Diabetes 1999; 48:2182–2188.

    Article  CAS  PubMed  Google Scholar 

  19. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 1998;19(4):477–490.

    Article  CAS  PubMed  Google Scholar 

  20. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000;106(4):473–481.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486–2497.

    Google Scholar 

  22. Groop LC. Insulin resistance: the fundamental trigger of type 2 diabetes. Diabetes Obes Metab 1999;1Suppl 1:S1-S7.

    Article  CAS  PubMed  Google Scholar 

  23. Reaven GM. Insulin resistance: a chicken that has come to roots. Ann NY Acad Sci 1999;892:45–57.

    Article  CAS  PubMed  Google Scholar 

  24. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287(3):356–359.

    Article  PubMed  Google Scholar 

  25. Familiar Medical Quotations. Little, Brown, Boston, 1968.

  26. Bergman RN, Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 2000;11(9): 351–356.

    Article  CAS  PubMed  Google Scholar 

  27. Boyko EJ, Fujimoto WY, Leonetti DL, Newell-Morris L. Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care 2000;23(4):465–471.

    Article  CAS  PubMed  Google Scholar 

  28. Fujimoto WY. The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus. Am J Med 2000;108 Suppl 6a: 9S-14S.

    Article  CAS  PubMed  Google Scholar 

  29. Banerji M, Chaiken R, Gordon D, Kral J, Lebovitz H. Does intra-abdominal adipose tissue in black men determine whether NIDDM is insulin-resistant or insulin-sensitive? Diabetes 1995;44:141–146.

    Article  CAS  PubMed  Google Scholar 

  30. Carey D, Jenkins A, Campbell L, Freund J, Chisholm D. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996;45:633–638.

    Article  CAS  PubMed  Google Scholar 

  31. Bak J, Moller N, Schmitz O, Saaek A, Pedersen O. In vivo action and muscle glycogen synthase activity in type II (noninsulin dependent) diabetes mellitus: effects of diet treatment. Diabetologia 1992;35:777–784.

    CAS  PubMed  Google Scholar 

  32. Beck-Nielsen H, Pedersen O, Lindskov H. Normalization of the insulin sensitivity and the cellular insulin binding during treatment of obese diabetics for one year. Acta Endocrinol (Copenh) 1979;90:103–112.

    CAS  Google Scholar 

  33. Freidenberg G, Reichart D, Olefsky J, Henry R. Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus: effect of weight loss. J Clin Invest 1988;82:1398–1406.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Long S, O’Brien K, MacDonald K Jr, et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study. Diabetes Care 1994;17:372–375.

    Article  CAS  PubMed  Google Scholar 

  35. Pan X-R, Li G-W, Hu Y-H, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537–544.

    Article  CAS  PubMed  Google Scholar 

  36. Knowler W, Barrett-Connor E, Fowler S, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403.

    Article  CAS  PubMed  Google Scholar 

  37. Tuomilehto J, Lindström J, Eriksson J, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350.

    Article  CAS  PubMed  Google Scholar 

  38. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003;238(4):467–484.

    PubMed  PubMed Central  Google Scholar 

  39. Boden G. Free fatty acids, insulin resistance, and type 2 diabetes mellitus. Proc Assoc Am Physicians 1999;111(3):241–248.

    Article  CAS  PubMed  Google Scholar 

  40. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002;51(1): 7–18.

    Article  CAS  PubMed  Google Scholar 

  41. Steppan C, Bailey S, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307–312.

    Article  CAS  PubMed  Google Scholar 

  42. McTernan PG, Fisher FM, Valsamakis G, et al. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 2003;88(12):6098–6106.

    Article  CAS  PubMed  Google Scholar 

  43. Wang H, Chu WS, Hemphill C, Elbein SC. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J Clin Endocrinol Metab 2002;87(6):2520–2524.

    Article  CAS  PubMed  Google Scholar 

  44. Engert JC, Vohl MC, Williams SM, et al. 5′ flanking variants of resistin are associated with obesity. Diabetes 2002;51(5):1629–1634.

    Article  CAS  PubMed  Google Scholar 

  45. Sentinelli F, Romeo S, Arca M, et al. Human resistin gene, obesity, and type 2 diabetes: mutation analysis and population study. Diabetes 2002;51(3):860–862.

    Article  CAS  PubMed  Google Scholar 

  46. Osawa H, Onuma H, Murakami A, et al. Systematic search for single nucleotide polymorphisms in the resistin gene: the absence of evidence for the association of three identified single nucleotide polymorphisms with Japanese type 2 diabetes. Diabetes 2002;51(3):863–866.

    Article  CAS  PubMed  Google Scholar 

  47. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004; 24(1):29–33.

    Article  CAS  PubMed  Google Scholar 

  48. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003;148(3): 293–300.

    Article  CAS  PubMed  Google Scholar 

  49. Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 2004;53Suppl I S143-S151.

    Article  CAS  PubMed  Google Scholar 

  50. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7(8):941–946.

    Article  CAS  PubMed  Google Scholar 

  51. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001;98(4):2005–2010.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50(9):2094–2099.

    Article  CAS  PubMed  Google Scholar 

  53. Tsao TS, Lodish HF, Fruebis J. ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol 2002;440(2–3): 213–221.

    Article  CAS  PubMed  Google Scholar 

  54. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 2002;105(23):2696–2698.

    Article  PubMed  Google Scholar 

  55. Hotamisligil G, Shargill N, Spiegelman B. Adipose expression of tumor necrosis factor a: direct role in obesity-linked resistance. Science 1993;259:87–91.

    Article  CAS  PubMed  Google Scholar 

  56. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95(5):2409–2415.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003;289(14):1799–1804.

    Article  CAS  PubMed  Google Scholar 

  58. Bruun JM, Pedersen SB, Richelsen B. Regulation of interleukin 8 production and gene expression in human adipose tissue in vitro. J Clin Endocrinol Metab 2001;86(3):1267–1273.

    CAS  PubMed  Google Scholar 

  59. Straczkowski M, Dzienis-Straczkowska S, Stepien A, Kowalska I, Szelachowska M, Kinalska I. Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system. J Clin Endocrinol Metab 2002; 87(10):4602–4606.

    Article  CAS  PubMed  Google Scholar 

  60. Nyholm B, Mengel A, Nielsen S, Moller N, Schmitz O. The insulin resistance of relatives of type 2 diabetic subjects is significantly related to a reduced VO2 max. Diabetologia 37, A28 1994.

    Google Scholar 

  61. Swinburn B. Effects of dietary lipid on insulin action. Clinical Studies. Ann NY Acad Sci 1993;683:102–109.

    Article  CAS  PubMed  Google Scholar 

  62. Pandit M, Burke J, Gustafson A, Minocha A, Peiris A. Drug-induced disorders of glucose tolerance. Ann Int Med 1993;118:529–539.

    Article  CAS  PubMed  Google Scholar 

  63. Yki-Järvinen H. Glucose toxicity. Endocr Rev 1992;13:415–431.

    PubMed  Google Scholar 

  64. Stern MP. Strategies and prospects for finding insulin resistance genes. J Clin Invest 2000;106(3):323–327.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Vaag A. On the pathophysiology of late onset non-insulin dependent diabetes mellitus. Current controversies and new insights. Dan Med Bull 1999;46(3):197–234.

    CAS  PubMed  Google Scholar 

  66. Kahn CR, Bruning JC, Michael MD, Kulkarni RN. Knockout mice challenge our concepts of glucose homeostasis and the pathogenesis of diabetes mellitus. J Pediatr Endocrinol Metab 2000;13Suppl 6: 1377–1384.

    PubMed  Google Scholar 

  67. McIntyre EA, Walker M. Genetics of type 2 diabetes and insulin resistance: knowledge from huma studies. Clin Endocrinol (Oxf) 2002;57(3):303–311.

    Article  CAS  Google Scholar 

  68. Gerich J. Role of insulin resistance in the pathogenesis of type 2 (noninsulin-dependent) diabetes mellitus. Bailliere’s Clinical Endocrinology and Metabolism 1988;2:307–326.

    Article  CAS  PubMed  Google Scholar 

  69. Burks DJ, White MF. IRS proteins and beta-cell function. Diabetes 2001;50:Suppl 1:S140-S145.

    Article  CAS  PubMed  Google Scholar 

  70. Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000;106(3):329–333.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Kahn S. The importance of the β-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med 2000;108(Suppl 6A):2S-8S.

    Article  CAS  PubMed  Google Scholar 

  72. Porte D. β-cells in type II diabetes mellitus. Diabetes 1991;40: 166–180.

    Article  PubMed  Google Scholar 

  73. Karam J, Forsham P. Pancreatic hormones and diabetes mellitus. In: Basic and Clinical Endocrinology. (Greenspan F, Baxter J, eds.). Appleton & Lange, Norwalk, CT, 1994, 571–634.

    Google Scholar 

  74. Gin H, Rigalleau V. Post-prandial hyperglycemia. post prandial hyperglycemia and diabetes. Diabetes Metab 2000;26(4):265–272.

    CAS  PubMed  Google Scholar 

  75. Pigon J, Giacca A, Ostenson C-G, Lam L, Vranic M., Efendic S. Normal hepatic insulin sensitivity in lean mild noninsulin-dependent diabetic patients. J Clin Endocrinol Metab 1996;81: 3702–3708.

    CAS  PubMed  Google Scholar 

  76. Polonsky KS. Evolution of beta-cell dysfunction in impaired glucose tolerance and diabetes. Exp Clin Endocrinol Diabetes 1999;107 Suppl 4:S124-S127.

    Article  CAS  PubMed  Google Scholar 

  77. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC, Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52(1):102–110.

    Article  CAS  PubMed  Google Scholar 

  78. Guiot Y, Sempoux C, Moulin P, Rahier J. No decrease of the beta-cell mass in type 2 diabetic patients. Diabetes 2001;50(Suppl 1):S188.

    Article  Google Scholar 

  79. Sakuraba H, Mizukami H, Yagihashi N., Wada R, Hanyu C, Yagihashi S. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 2002;45(1):85–96.

    Article  CAS  PubMed  Google Scholar 

  80. Deng S, Vatamaniuk M, Huang X, et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 2004;53(3):624–632.

    Article  CAS  PubMed  Google Scholar 

  81. Vague P, Moulin J-P. The defective glucose sensitivity of the B cell in noninsulin dependent diabetes: improvement after twenty hours of normoglycemia. Metabolism 1982;31:139–142.

    Article  CAS  PubMed  Google Scholar 

  82. Rossetti L, Giaccari A, DeFronzo R. Glucose Toxicity. Diabetes Care 1990;13:610–630.

    Article  CAS  PubMed  Google Scholar 

  83. Unger R. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995;44:863–870.

    Article  CAS  PubMed  Google Scholar 

  84. Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA 1998;95(5):2498–2502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Kahn S. The importance of β-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001;86: 4047–4058.

    CAS  PubMed  Google Scholar 

  86. Levy J, Atkinson A, Bell P, McCance D, Hadden D. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year, follow-up of the Belfast Diet Study. Diabetic Med 1998:15:290–296.

    Article  CAS  PubMed  Google Scholar 

  87. Inzucchi S. Dral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360–372.

    Article  CAS  PubMed  Google Scholar 

  88. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004:27(7):1535–1540.

    Article  PubMed  Google Scholar 

  89. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus. the AACE system of intensive diabetes self-managment—2000 update. Endocr Pract 2000;6(1):43–84.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Rochester School of Medicine, 601 Elmwood Ave, Box MED/CRC, 14642, Rochester, NY

    Ervin Szoke & John E. Gerich MD

Authors
  1. Ervin Szoke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John E. Gerich MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John E. Gerich MD.

Additional information

The authors have stated that they do not have a significant financial interest or other relationship with any product manufacturer or provider of services discussed in this article. The authors also do not discuss the use of off-label products, which includes unlabeled, unapproved, or investigative products or devices.

About this article

Cite this article

Szoke, E., Gerich, J.E. Role of impaired insulin secretion and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Compr Ther 31, 106–112 (2005). https://doi.org/10.1007/s12019-005-0005-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12019-005-0005-y

Keywords

Search

Navigation